Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02558868 | Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer | completed | Phase 2 | 80 | Zhejiang UniversityOTHER | 1 | Jun 21, 2018 |
| clinicaltrials |
| NCT03498326 | Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer(GCRP) | recruiting | Phase 2 | 480 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01389440 | Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer(GEMCAD1003) | completed | Phase 2 | 24 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT00417287 | Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 17 | Cascadian Therapeutics Inc.INDUSTRY | 1 | May 16, 2018 | clinicaltrials |
| NCT01373164 | A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 170 | Eli Lilly and CompanyINDUSTRY | 6 | May 16, 2018 | clinicaltrials |
| NCT00889187 | Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT01417000 | Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer | completed | Phase 2 | 93 | Aduro Biotech, Inc.INDUSTRY | 1 | May 8, 2018 | clinicaltrials |
| NCT01458717 | Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer | completed | Phase 2 / Phase 3 | 58 | Seoul National University HospitalOTHER | 1 | May 2, 2018 | clinicaltrials |
| NCT02284139 | Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects | completed | Phase 2 / Phase 3 | 90 | Dong-A University HospitalOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT03502343 | Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer | unknown | Phase 2 | 52 | Yonsei UniversityOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT00839332 | A Study for Participants With Pancreatic Cancer | completed | Phase 1 / Phase 2 | 157 | Eli Lilly and CompanyINDUSTRY | 6 | Apr 17, 2018 | clinicaltrials |
| NCT01888978 | Molecularly Tailored Therapy for Pancreas Cancer | completed | Phase 2 | 19 | Georgetown UniversityOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | terminated | Phase 2 | 5 | University of OklahomaOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT01423604 | Study of Ruxolitinib in Pancreatic Cancer Patients(RECAP) | completed | Phase 2 | 136 | Incyte CorporationINDUSTRY | 1 | Feb 12, 2018 | clinicaltrials |
| NCT01851174 | Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer | terminated | Phase 2 | 15 | Western Regional Medical CenterOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT02806648 | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)(PALBONET) | completed | Phase 2 | 21 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00365144 | Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01781520 | Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Capital Medical UniversityOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02978547 | The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma(Metformin 001) | unknown | Phase 2 | 20 | British Columbia Cancer AgencyOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT00810719 | Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer | completed | Phase 2 | 30 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01234935 | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | completed | Phase 2 | 8 | Translational Oncology Research InternationalOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00426127 | Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 2 | University of IowaOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT00262951 | Chemoradiation in Locally Advanced Pancreatic Cancer | terminated | Phase 2 | 23 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01056601 | Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy | terminated | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01146054 | Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma | completed | Phase 2 | 59 | Stanford UniversityOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT00463840 | Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00290693 | Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer | completed | Phase 2 | 45 | University of MiamiOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00201838 | Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma | completed | Phase 1 / Phase 2 | 38 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT01430052 | Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer | completed | Phase 2 | 110 | Osaka Medical Center for Cancer and Cardiovascular DiseasesOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT02862015 | Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients(Oncothermia) | unknown | Phase 2 | 100 | Seoul National University HospitalOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT00383760 | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT03316326 | S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer | unknown | Phase 2 | 35 | National Taiwan University HospitalOTHER | 0 | Oct 20, 2017 | clinicaltrials |
| NCT00833859 | Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 9, 2017 | clinicaltrials |
| NCT01688336 | FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 9 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT02017015 | Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer(PANC-001) | completed | Phase 2 | 83 | CelgeneINDUSTRY | 1 | Sep 26, 2017 | clinicaltrials |
| NCT01971281 | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | unknown | Phase 1 / Phase 2 | 40 | NovoCure Ltd.INDUSTRY | 2 | Sep 13, 2017 | clinicaltrials |
| NCT03278015 | Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients | unknown | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT01553019 | Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer(PC03) | completed | Phase 2 | 2 | University of FloridaOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01150630 | Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer(PACT-15) | completed | Phase 2 | 98 | IRCCS San RaffaeleOTHER | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01730222 | A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma(PACT-19) | completed | Phase 1 / Phase 2 | 137 | IRCCS San RaffaeleOTHER | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01523457 | Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer(FOLFIRINOX) | completed | Phase 2 | 75 | Yale UniversityOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT01531712 | Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable | terminated | Phase 2 | 6 | Institut Català d'OncologiaOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT03167112 | A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer(Folfirinox) | unknown | Phase 2 | 20 | Petr KavanOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01693419 | S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer | completed | Phase 2 | 37 | Hallym University Medical CenterOTHER | 1 | Aug 23, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2018source: clinicaltrials